Patient ’s experience and satisfaction with self-administered subcutaneous depot medroxyprogesterone acetate use during the first year of COVID-19

Self-administered subcutaneous (SC) depot medroxyprogesterone acetate (DMPA) can improve contraception access by eliminating the visit at a health center for administration.For the patients at our New York City health centers who were offered a switch to self-administered DMPA-SC at the onset of the coronavirus disease 2019 (COVID-19) pandemic, we sought to understand their experience of choosing to switch, their experience accessing and using the method, and their method satisfaction.

Source: Contraception - March 15, 2023 Category: OBGYN Authors: Tiffany Joyce Smith, Talia K Urdanigo, Nandini Shroff, Susan E Rubin Tags: Original Research Article Source Type: research